[종합] Celltrion reduces the incidence of critically ill patients by 54% in phase 2 clinical trials of corona antibody treatment… Recovery period ↓
![[종합] Celltrion reduces the incidence of critically ill patients by 54% in phase 2 clinical trials of corona antibody treatment… Recovery period ↓](https://image.ajunews.com/content/image/2021/01/13/20210113235100686144.jpg "[종합] Celltrion reduces the incidence of critically ill patients by 54% in phase 2 clinical trials of corona antibody treatment… Recovery period ↓")
